{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:22:59Z","timestamp":1790241779850,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Adverse events (AEs) are frequently reported in clinical trials of advanced therapies for ulcerative colitis (UC). It remains uncertain whether patients receiving concomitant corticosteroids experience higher AE rates. This study aimed to determine whether corticosteroid use is associated with increased AEs in UC trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This post-hoc analysis used participant-level data from several placebo-controlled trials (GEMINI-1, ULTRA-2, VARSITY, ACT-1, OCTAVE, and PURSUIT). The primary population included induction responders with or without baseline corticosteroid use. The primary outcome assessed the association between corticosteroid use and total AEs. Secondary outcomes included AE rates among those who achieved corticosteroid-free remission versus those who did not, and whether specific AEs were more common in corticosteroid users.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 2339 patients who achieved clinical response after induction, 1159 (49.5%) used corticosteroids at baseline. By 1\u2009year, AE incidence was higher among corticosteroid users than non-users (75.2% vs. 67.6%, P\u2009&amp;lt;\u2009.001). Patients who achieved corticosteroid-free remission had fewer AEs than those who did not (67.4% vs. 77.5%, P\u2009&amp;lt;\u2009.001). Moderate AEs were more frequent among corticosteroid users. Common AEs included infections (in both groups) and liver abnormalities (more in corticosteroid users). Multivariable logistic regression confirmed baseline corticosteroid use as an independent AE risk factor [odds ratio (OR) 1.5, 95% CI 1.3\u20131.8, P\u2009=\u2009.002]. Ongoing corticosteroid use at 1\u2009year was associated with even higher AE risk (OR 4.6, 95% CI 2.1\u20136.8, P\u2009&amp;lt;\u2009.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Corticosteroid use is independently associated with increased AEs in UC clinical trials. Continued monitoring and strategies for corticosteroid tapering may reduce AE burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf145","type":"journal-article","created":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T11:43:44Z","timestamp":1754135024000},"source":"Crossref","is-referenced-by-count":3,"title":["Impact of concomitant corticosteroid use on adverse events in ulcerative colitis clinical trials"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6999-3125","authenticated-orcid":false,"given":"Hasan","family":"Hamam","sequence":"first","affiliation":[{"name":"Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University , Hamilton, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parambir S","family":"Dulai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Northwestern University , Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K","family":"Marshall","sequence":"additional","affiliation":[{"name":"Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University , Hamilton, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4698-9948","authenticated-orcid":false,"given":"Christopher","family":"Ma","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Departments of Medicine and Community Health Sciences, University of Calgary , Calgary, AB,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Western University , London, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-091X","authenticated-orcid":false,"given":"Walter","family":"Reinisch","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1536-8436","authenticated-orcid":false,"given":"Neeraj","family":"Narula","sequence":"additional","affiliation":[{"name":"Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University , Hamilton, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"2025092419312612100_jjaf145-B1","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/14740338.2017.1340936","article-title":"The safety of non-biological treatments in Ulcerative Colitis","volume":"16","author":"Troncone","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"2025092419312612100_jjaf145-B2","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.cgh.2013.09.006","article-title":"Treat to target: a proposed new paradigm for the management of Crohn's disease","volume":"13","author":"Bouguen","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025092419312612100_jjaf145-B3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1053\/j.gastro.2014.08.044","article-title":"Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases","volume":"147","author":"Danese","year":"2014","journal-title":"Gastroenterology"},{"key":"2025092419312612100_jjaf145-B4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.bpg.2010.01.002","article-title":"Adverse effects of biologics used for treating IBD","volume":"24","author":"Stallmach","year":"2010","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2025092419312612100_jjaf145-B5","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/MIB.0000000000001049","article-title":"Risk for overall infection with Anti-TNF and Anti-integrin agents used in IBD: a systematic review and meta-analysis","volume":"23","author":"Shah","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2025092419312612100_jjaf145-B6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"key":"2025092419312612100_jjaf145-B7","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"2025092419312612100_jjaf145-B8","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the TREAT registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"2025092419312612100_jjaf145-B9","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1136\/gut.2008.163642","article-title":"Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study","volume":"58","author":"Fidder","year":"2009","journal-title":"Gut"},{"key":"2025092419312612100_jjaf145-B10","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.3748\/wjg.15.2067","article-title":"Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease","volume":"15","author":"Hoentjen","year":"2009","journal-title":"World J Gastroenterol"},{"key":"2025092419312612100_jjaf145-B11","doi-asserted-by":"crossref","first-page":"e0158017","DOI":"10.1371\/journal.pone.0158017","article-title":"Corticosteroid use and complications in a US inflammatory bowel disease cohort","volume":"11","author":"Waljee","year":"2016","journal-title":"PLoS One"},{"key":"2025092419312612100_jjaf145-B12","first-page":"1972","article-title":"Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study","volume":"160","author":"Chalasani","year":"2021","journal-title":"Gastroenterology"},{"key":"2025092419312612100_jjaf145-B13","author":"NCBI Bookshelf","year":"2021"},{"key":"2025092419312612100_jjaf145-B14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1677\/JOE-08-0054","article-title":"Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome","volume":"197","author":"Macfarlane","year":"2008","journal-title":"J Endocrinol"},{"key":"2025092419312612100_jjaf145-B15","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/ecco-jcc\/jjz151","article-title":"Influence of drug exposure on vedolizumab-induced endoscopic remission in anti-TNF naive patients with ulcerative colitis","volume":"14","author":"Verstockt","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2025092419312612100_jjaf145-B16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cgh.2019.02.044","article-title":"Comparative risk of serious infections with biologic and\/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025092419312612100_jjaf145-B17","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1038\/ajg.2014.313","article-title":"Oral corticosteroids and the risk of serious infections in patients with elderly-onset inflammatory bowel diseases","volume":"109","author":"Brassard","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"2025092419312612100_jjaf145-B18","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/clinids\/11.6.954","article-title":"Risk of infectious complications in patients taking glucocorticosteroids","volume":"11","author":"Stuck","year":"1989","journal-title":"Rev Infect Dis"},{"key":"2025092419312612100_jjaf145-B19","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1097\/MIB.0000000000000754","article-title":"Comparative effectiveness of infliximab and adalimumab in Crohn\u2019s disease and ulcerative colitis","volume":"22","author":"Ananthakrishnan","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2025092419312612100_jjaf145-B20","first-page":"34","article-title":"Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis","volume":"72","author":"Burr","year":"2023","journal-title":"Gut"},{"key":"2025092419312612100_jjaf145-B21","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/jpn3.12246","article-title":"Standardizing steroid protocols for newly diagnosed inflammatory bowel disease patients: a quality improvement initiative","volume":"79","author":"Lendner","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2025092419312612100_jjaf145-B22","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"2025092419312612100_jjaf145-B23","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/ajg.2016.236","article-title":"The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn\u2019s disease: results from the US VICTORY Consortium","volume":"111","author":"Dulai","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2025092419312612100_jjaf145-B24","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/ibd\/izz193","article-title":"Corticosteroid-free remission vs overall remission in clinical trials of moderate\u2013severe ulcerative colitis and Crohn\u2019s","volume":"26","author":"George","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2025092419312612100_jjaf145-B25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/ajg.2017.479","article-title":"Increased mortality rates with prolonged corticosteroid therapy when compared with antitumor necrosis factor-\u03b1-directed therapy for inflammatory bowel disease","volume":"113","author":"Lewis","year":"2018","journal-title":"Am J Gastroenterol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf145\/63961165\/jjaf145.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/8\/jjaf145\/63961165\/jjaf145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/8\/jjaf145\/63961165\/jjaf145.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T23:31:34Z","timestamp":1758756694000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf145\/8222725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,9,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf145","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,8]]},"article-number":"jjaf145"}}